Allogeneic plasmacytoid dendritic cells expressing lung tumor antigens PDC*lung01

{
  "id": "MLC-T-ONC-009938",
  "term": "Allogeneic plasmacytoid dendritic cells expressing lung tumor antigens PDC*lung01",
  "field": "Oncology and biomedicine",
  "definition": "An off-the-shelf (OTS) preparation composed of irradiated allogeneic plasmacytoid dendritic cells (pDCs) loaded with seven immunogenic, human leukocyte antigen (HLA)-A*02:01 serotype-restricted peptides derived from the lung tumor antigens cancer/testis antigen 1 (NY-ESO-1), melanoma antigen A3 (MAGE-A3), MAGE-A4, multi-MAGE, a peptide shared by multiple MAGE-A proteins, survivin, mucin1 (MUC1) and melanoma antigen recognized by T cells 1 (Mart-1; Melan-A), with potential immunostimulating and antineoplastic activities. Upon administration of the allogeneic pDCs expressing lung tumor antigens PDC*lung01, the pDCs may activate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against HLA-A*0201 positive lung cancer cells expressing the TAAs NY-ESO-1, MAGE-A3, MAGEA4, multi-MAGE, survivin, MUC1 and melan-A. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.",
  "synonyms": [
    "therapeutic cancer vaccine PDC*lung01",
    "allogeneic pDCs- expressing lung tumor antigens PDC*lung01"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-plasmacytoid-dendritic-cells-expressing-lung-tumor-antigens-pdc/"
}